Single-cell RNA-seq data from 3 HGSOC patient-derived organoids and corresponding tumor or ascites

The broad research use of organoids from high-grade serous ovarian carcinoma (HGSOC) has been hampered by low success rates of culture establishment and scarcity of fresh tumor material. Here we describe a novel method that enabled generation and long-term expansion of a HGSOC organoid biobank with efficacy markedly improved over previous reports (55% vs. 23-38%). We established organoids from cryopreserved material, demonstrating the feasibility of using frozen tissue biobanks for HGSOC organoid derivation. Organoids recapitulated patient-specific genomic landscapes and retained the phenotypic heterogeneity of original samples. Organoid drug responses correlated with clinical treatment outcomes, but only for organoids maintained in human plasma-like medium (HPLM), highlighting the importance of relevant culture conditions in organoid-based functional assays. Taken together, we introduce a resource for efficient development and use of HGSOC organoids from cryopreserved material in ovarian cancer research.EGA study EGAS00001006246